Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo study, which was claimed to have fundamentally flawed statistical assumptions and was unlikely to achieve statistical significance. Investors who suffered losses are encouraged to join the case and have until September 14, 2026, to request appointment as lead plaintiff.